LFST earnings analysis
What we found in LFST's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
LifeStance Health Group reported strong results for Q1 2026, with revenues of $403.5 million, a 21% increase from the prior year. Diluted EPS was $0.04, slightly below expectations, but the company saw significant growth in patient visits and clinician hiring, which supports a bullish outlook for the year ahead.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Growth of 21% YoY
- Q1 2026 revenue reached $403.5 million, up from $333.0 million in Q1 2025, driven by a 18% increase in patient visits.
- Increased EPS Performance
- Diluted EPS for Q1 2026 was reported at $0.04, though slightly below the estimated $0.05.
- Clinician Base Expanded
- Total clinicians increased by 814 to 8,349, enabling more patient visits and revenue growth.
- Robust Operating Income
- Operating income rose to $22.3 million in Q1 2026, compared to $1.6 million in Q1 2025.
- Cash Flow from Operations Positive
- Operating cash flow generated $33.1 million in Q1 2026, in contrast to a negative cash flow of $3.1 million in Q1 2025.
- Significant Free Cash Flow Recovery
- Free cash flow improved to $19.2 million from a negative $10 million a year earlier.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Dependence on Insurance Payments
- Continued reliance on third-party payors could impact revenue stability, as changes in reimbursement rates may occur.
- Rising Operational Costs
- General and administrative expenses increased by 6% to $100.3 million, potentially affecting profitability.
- Material Weakness in Internal Controls
- Ongoing material weaknesses in financial reporting could pose risks to reliable reporting and operational effectiveness.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.04
- Operating margin
- 5.5%
What they said about what is next.
LifeStance raised its full-year revenue guidance to between $1.640 billion and $1.680 billion, citing robust operational performance.
The filing reads better than the one before it.
What came before.
- 10-K · February 25, 2026
- LifeStance positions itself as a tech-enabled hybrid (virtual + in-person) outpatient mental health platform anchored by scale, an employed clinician model and in‑network payor relationships. Operational scale is large…
- 10-K · February 27, 2025
- LifeStance describes a tech-enabled hybrid (virtual + in-person) outpatient mental health platform anchored by scale, in‑network payor relationships and an employed clinician model. Operational metrics show substantial…
- 10-Q · August 8, 2024
- LifeStance reported Q2 total revenue of $312.3M, up 20.3% year-over-year and +3.9% sequentially. Operating loss narrowed to $(15.95)M (operating margin -5.11%) from $(48.41)M in Q2 2023, and GAAP net loss per share…
- 10-Q · May 9, 2024
- LifeStance reported Q1 revenue of $300,437,000, up $47,848,000 (≈19.0%) versus Q1 2023, with operating loss narrowing to $16,772,000 from $34,093,000 a year ago. Net loss per share improved to $(0.06) from $(0.09) and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LFST makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever